Cefazolin sodium is a broad-spectrum antibiotic useful for the treatment of many Gram-positive and some Gram-negative bacterial infections. This study was designed to investigate the impact of The Trivedi Effect®-Biofield Energy Healing Treatment on the structural properties and the isotopic abundance ratio of cefazolin sodium using LC-MS and GC-MS spectroscopy. Cefazolin sodium sample was divided into two parts, one part of cefazolin sodium was considered as control (no Biofield Energy Treatment was provided), while the second part was treated with The Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a renowned Biofield Energy Healer, Alice Branton and termed as a treated sample. The LC-MS spectra of both the samples of cefazolin sodium at the retention time (Rt) 4.6 minutes exhibited the mass of the protonated molecular ion peak at m/z 455 [M+H]+ (calculated for C14H15N8O4S3 +, 455.05). The LC-MS based isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O or 33S/32S) in the treated cefazolin was significantly increased by 18.90% compared with the control sample. Thus, 13C, 2H, 15N, 17O and 33S contributions from (C14H15N8O4S3)+ to m/z 456 in the treated sample were significantly increased compared with the control sample. In the GC-MS the retention times of the treated sample (15.25 minute) was found to be very close to the control sample (15.24 minutes). The mass peak intensities of the control sample at m/z 56, 132, 219, and 264 were significantly decreased by 33.51%, 44.74%, 66.26%, and 73.77%, respectively compared to the Biofield Energy Treated sample (Table 2). Hence, 13C, 2H, 15N, 17O, and 33S contributions from (C14H15N8O4S3)+ to m/z 456 in the treated sample were significantly increased compared with the control sample. The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O or 33S/32S) and peak intensities in the treated cefazolin sodium was significantly altered compared to the control sample. The new form of treated cefazolin sodium would be better designing novel pharmaceutical formulations that might offer better therapeutic response against cellulitis, respiratory tract infections, urinary tract infections (UTI), genital infections, joint infection, biliary tract infections, pneumonia, endocarditis, blood infections (sepsis), and also prevent group B streptococcal disease at the time of delivery and before surgery, etc.
